Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Annexa

- PMLiVE

BMS names Giovanni Caforia as new CEO

Current chief operating officer will succeed Lamberto Andreotti in May

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo set for early access in UK

First anti-PD1 to be given fast-track status in the country

Bristol-Myers Squibb (BMS) building

Opdivo to be tested as ‘double immunotherapy’ for tumours

BMS and Ono to test anti-PD-1 in combination with Kyowa Hakko's mogamulizumab

- PMLiVE

ASH: Pradaxa antidote effective in key patient groups

Boehringer posts positive data on use of idarucizumab in elderly and people with kidney impairment

- PMLiVE

PD-1 inhibitors shine at ASH conference

New data suggests the immunotherapy class could be also used for haematological cancers

Bristol-Myers Squibb (BMS) building

BMS to fund hepatitis projects in China and India

Pharma firm awards nine grants to support care for high-risk patients

- PMLiVE

BMS’ daclatasvir scuppered by decision to drop companion drug

FDA denies approval due to discontinuation of asunaprevir development

- PMLiVE

Integrating digital: developing a social conference

Boehringer Ingelheim’s director of oncology Albert van Eijk on the digital elements of its multichannel efforts

Bristol-Myers Squibb (BMS) building

BMS takes option to buy fibrosis firm Galecto

The Swedish biotech has a pulmonary fibrosis candidate in early-stage testing

- PMLiVE

BMS expand biologics manufacturing deal with Lonza

Will make wider use of New Hampshire facilities ahead of product launch

- PMLiVE

NICE backs Boehringer’s blood clot treatment Pradaxa

Draft DVT and PE guidance puts it on course to catch up with Bayer's Xarelto

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links